Polycomb EZH1 regulates cell cycle/5-fluorouracil sensitivity of neuroblastoma cells in concert with MYCN

Cancer Sci. 2022 Dec;113(12):4193-4206. doi: 10.1111/cas.15555. Epub 2022 Oct 7.

Abstract

In the present study, we found that EZH1 depletion in MYCN-amplified neuroblastoma cells resulted in significant cell death as well as xenograft inhibition. EZH1 depletion decreased the level of H3K27me1; the interaction and protein stabilization of MYCN and EZH1 appear to play roles in epigenetic transcriptional regulation. Transcriptome analysis of EZH1-depleted cells resulted in downregulation of the cell cycle progression-related pathway. In particular, Gene Set Enrichment Analysis revealed downregulation of reactome E2F-mediated regulation of DNA replication along with key genes of this process, TYMS, POLA2, and CCNA1. TYMS and POLA2 were transcriptionally activated by MYCN and EZH1-related epigenetic modification. Treatment with the EZH1/2 inhibitor UNC1999 also induced cell death, decreased H3K27 methylation, and reduced the levels of TYMS in neuroblastoma cells. Previous reports indicated neuroblastoma cells are resistant to 5-fluorouracil (5-FU) and TYMS (encoding thymidylate synthetase) has been considered the primary site of action for folate analogues. Intriguingly, UNC1999 treatment significantly sensitized MYCN-amplified neuroblastoma cells to 5-FU treatment, suggesting that EZH inhibition could be an effective strategy for development of a new epigenetic treatment for neuroblastoma.

Keywords: 5-FU; EZH1; MYCN; TYMS; neuroblastoma.

MeSH terms

  • Animals
  • Cell Cycle
  • Cell Line, Tumor
  • Fluorouracil
  • Gene Expression Regulation, Neoplastic
  • Humans
  • N-Myc Proto-Oncogene Protein / genetics
  • Neuroblastoma* / drug therapy
  • Neuroblastoma* / genetics
  • Neuroblastoma* / metabolism
  • Polycomb Repressive Complex 2* / genetics

Substances

  • EZH1 protein, human
  • Fluorouracil
  • MYCN protein, human
  • N-Myc Proto-Oncogene Protein
  • Polycomb Repressive Complex 2